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Cinaciguat (BAY 58–2667) Improves Cardiopulmonary
Hemodynamics in Patients With Acute Decompensated
Heart Failure
Harald Lapp, MD; Veselin Mitrovic, MD; Norbert Franz, MD; Hubertus Heuer, MD;
Michael Buerke, MD; Judith Wolfertz, MD; Wolfgang Mueck, PhD; Sigrun Unger, MSc;
Georg Wensing, MD; Reiner Frey, MD
Background—Cinaciguat (BAY 58–2667) is the first of a new class of soluble guanylate cyclase activators in clinical
development for acute decompensated heart failure. We aimed to assess the hemodynamic effects, safety, and tolerability of
intravenous cinaciguat in patients with acute decompensated heart failure (pulmonary capillary wedge pressure 18 mm Hg).
Methods and Results—After initial dose finding (part A; n27), cinaciguat was evaluated in the nonrandomized,
uncontrolled proof-of-concept part of the study (part B; n33) using a starting dose of 100 g/h, which could be titrated
depending on hemodynamic response. Patients were categorized as responders if their pulmonary capillary wedge
pressure decreased by 4 mm Hg compared with baseline. Final doses of cinaciguat after 6 hours of infusion in part
B were 50 g/h (n2), 200 g/h (n12), and 400 g/h (n16). Compared with baseline, a 6-hour infusion of
cinaciguat led to significant reductions in pulmonary capillary wedge pressure (7.9 mm Hg), mean right atrial pressure
(2.9 mm Hg), mean pulmonary artery pressure (6.5 mm Hg), pulmonary vascular resistance (43.4 dynes · s ·
cm5), and systemic vascular resistance (597 dynes · s · cm5), while increasing heart rate by 4.4 bpm and cardiac
output by 1.68 L/min. The responder rate was 53% after 2 hours, 83% after 4 hours, and 90% after 6 hours. Cinaciguat
was well tolerated, with 13 of 60 patients reporting 14 drug-related treatment-emergent adverse events of mild to
moderate intensity, most commonly hypotension.
Conclusions—Cinaciguat has potent preload- and afterload-reducing effects, increasing cardiac output. Further investi-
gation of cinaciguat for acute decompensated heart failure is warranted. (Circulation. 2009;119:2781-2788.)
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Improvements in the therapy of acute cardiovascular dis-eases and an aging population have increased the global
prevalence of heart failure (HF). In the 49 member states
represented by the European Society of Cardiology, an
estimated 10 million people suffer from HF,1 and an equal
number may have asymptomatic left ventricular dysfunction2;
globally, an estimated 23 million people have HF.3 HF is the
most common cause of hospitalization in the elderly.4 Pa-
tients with HF remain at substantial risk of acute decompen-
sated HF (ADHF), with nearly half of older patients with a
discharge diagnosis of HF being readmitted within 6 months.5
Mortality is high; 10% of patients die within 30 days.6
Editorial see p 2752
Clinical Perspective on p 2788
The underlying pathology of ADHF is characterized by
endothelial dysfunction, chronic vasoconstriction, an elevated
vascular resistance, and an increase in left ventricular end-
diastolic pressure (preload and afterload).7,8 In the healthy
endothelium, vascular tone and vasodilation are regulated by
cGMP, a second messenger produced by soluble guanylate
cyclase (sGC) in response to endogenous or exogenous nitric
oxide (NO).9 This pathway may be disrupted in ADHF
because of a decreased bioavailability of NO, together with
increases in oxidized and heme-free forms of sGC that are
insensitive to NO, resulting in insufficient vasodilation.10–12
Furthermore, although direct in vivo evidence for the exis-
tence of oxidized/heme-free sGC remains circumstantial, in
vivo experiments have shown that oxidative stress and related
vascular disease states led to an sGC that was indistinguish-
able from the in vitro oxidized/heme-free enzyme; thus, the
physiological existence of oxidized/heme-free sGC can no
longer be rejected.12–14
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Cinaciguat (BAY 58–2667) is a novel sGC activator in
clinical development for ADHF. In preclinical studies, ci-
naciguat has been shown to act on NO-nonresponsive sGC
and to induce vasodilation preferentially in diseased ves-
sels.11,12,15 The aim of this first study of intravenous ci-
naciguat in patients (proof of concept) was to assess hemo-




This nonrandomized, uncontrolled, unblinded, multicenter phase II
study consisted of an initial dose-finding part (part A) and a
proof-of-concept part (part B). Cinaciguat 0.005% (50 g/mL; Bayer
HealthCare AG, Wuppertal, Germany) was administered as an
intravenous infusion in 3 ascending dose steps. Each dose step lasted
2 hours, resulting in a total cinaciguat infusion period of 6 hours.
This ascending-dose design and the dose were chosen following the
results of a previous study in healthy volunteers, with the 2-hour
titration step based on the hemodynamic steady-state evaluation in
the same study.16
Two cohorts of patients participated in part A, with the dose steps
being 50, 100, and 200 g/h per subject in cohort 1 and 100, 200, and
400 g/h per subject in cohort 2 (Figure 1). Determination of the
optimal dose was based on the numbers of responders (defined as a
reduction in pulmonary capillary wedge pressure [PCWP] of
4 mm Hg compared with baseline without clinically relevant
adverse events) for each dose and on the number of patients
achieving a reduction of systolic blood pressure (SBP) to 100 to
110 mm Hg. (Note that a response of PCWP 4 mm Hg was based
on the results of the Vasodilation in the Management of Acute CHF
[VMAC] study,17 and the minimal SBP was 100 mm Hg according
to the protocol.) The decision to reduce or stop cinaciguat dose in
parts A and B was at the investigators’ discretion, although if
patients developed symptomatic hypotension or SBP dropped
below 80 mm Hg, the dose was stopped. In part B, dose titration
started with the optimal dose identified in part A, and individual
titration to target blood pressure was allowed after each 2-hour
period (Figure 1).
The study was carried out in accordance with the Declaration of
Helsinki and adhered to the International Conference of Harmoni-
zation good clinical practice guidelines and the German drug law.
The study protocol was approved by the Ethics Committee of the
Thuringia Medical Council, Jena, Germany, and the Bundesinstitut
für Arzneimittel und Medizinprodukte, Bonn, Germany.
Patients
Male and female patients 18 years of age who were admitted to
hospital for ADHF were eligible for inclusion in this study if they
had ongoing New York Heart Association class III or IV symptoms
with a PCWP 18 mm Hg and if parenteral pharmacotherapy with
invasive hemodynamic monitoring was clinically indicated. Unstable
patients; women of childbearing potential; patients with New York
Heart Association class I or II HF; those with acute HF requiring
acute cardiac intervention or surgery, cardiogenic shock, or catechol-
amines; patients needing invasive mechanical ventilation; and those
with renal failure (creatinine 2 mg/dL [177 mol/L]) were
excluded.
After admission to hospital with symptoms of ADHF, routine
diagnostic tests, administration of basic therapy (eg, inhaled oxygen,
diuretics, and morphine), and decisions about treatment (eg, indica-
tion for intravenous therapy and invasive hemodynamic monitoring),
eligible patients were informed about this study, asked to participate,
and allowed to give their informed consent. Before a cinaciguat
infusion was started, the patient’s medical history was taken, and a
physical examination was performed, including measurement of
heart rate, blood pressure, and ECG, and blood samples were taken
for safety laboratory tests. All long-term oral medications were
withheld before the start of the infusion and continued after the end
of the invasive part of the study (1-hour run-in, 6-hour cinaciguat
infusion, and 2-hour follow-up periods); intravenous diuretics were
permitted only if clinically indicated during this period. Inhaled
oxygen and morphine were allowed during the invasive period.
Hemodynamic Parameters
Patients underwent hemodynamic monitoring of SBP, diastolic
blood pressure, mean arterial pressure (calculated), and heart rate,
which were all measured noninvasively. The following parameters
were monitored with a Swan Ganz catheter throughout the invasive
period of the study: PCWP, mean right atrial pressure (RAP), mean
pulmonary artery pressure (PAP), pulmonary (PVR) and systemic
vascular resistance (SVR), and cardiac output. Hemodynamic pa-
rameters were measured immediately before the cinaciguat infusion
was started to establish baseline values. Commercially available
routine assay kits were used for hormone determinations.
Safety Monitoring
All patients underwent screening evaluations before participation in
the study. Subjective tolerability was monitored by reporting of
patients’ well-being, adverse events, New York Heart Association
class, and dyspnea score (using a 7-point Likert scale ranging from
3 [clear improvement] to 3 [clear deterioration/worsening]) as
described previously.17 As defined in the study protocol, patients
were questioned about their well-being compared with their baseline
condition, and their dyspnea score before hemodynamic measure-
ments was assessed in a nonpersuasive manner by a person not
involved in (or aware of) hemodynamic measurements and results.
Thus, patient-assessed dyspnea and well-being were blinded to
hemodynamic measurement.
Clinical adverse events were graded as mild, moderate, or severe
and according to whether or not they were considered serious.
Objective tolerability was measured by monitoring of vital signs and
ECGs, and laboratory parameters were assessed throughout the
study. Blood samples were taken at 0, 6, and 8 hours after the start
of cinaciguat infusion for measurement of atrial natriuretic peptide,
N-terminal prohormone brain natriuretic peptide (NT-proBNP), and
renin and noradrenaline concentrations. Follow-up monitoring
(physical examination, adverse event questioning, safety laboratory
tests, heart rate, blood pressure, and ECG) was carried out 8, 24, and
48 hours after the first administration of cinaciguat, with a final
examination at least 2 days after administration of cinaciguat or
before hospital discharge. The follow-up period for adverse events
was until final examination for all adverse events with active
follow-up and 5 days for serious adverse events with active follow-
up; after a further 25 days, the investigator reported any serious
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Figure 1. Cinaciguat dosing schedule in parts A and B.
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Statistical Analyses
The primary target prespecified in the protocol was the change in
PCWP observed 6 hours after the start of infusion compared with the
corresponding baseline value before administration. The statistical
analysis of all other changes was exploratory. Probability values
were calculated by means of a paired t test. Two-tailed probability
values (0.05) were calculated independently, and no adjustment
for multiple tests of different variables was performed. For tests
within a variable, the Bonferroni correction was applied, and
P0.05/40.0125 was required for statistical significance of any
given time point (Figure 2). Analyses were performed with the SAS
9.1 package (SAS Institute Inc, Cary, NC).
The authors had full access to and take full responsibility for the




In total, 60 patients with ADHF were enrolled from 7 study
centers and received the study drug: 12 patients in cohort 1 of
part A, 15 patients in cohort 2 of part A, and 33 patients in
part B (Table 1). Patient demographics were similar among
the 3 groups (Table 1), with the overall mean age being 65.8
years (range, 36 to 87 years) and the large majority (92%) of
the study population being male. All 60 patients were valid
for safety evaluation. In part B, 30 of 33 subjects were valid
for hemodynamic evaluation. The median time between
admission and first dose of cinaciguat was 2.08 days for
patients participating in part B.
Comorbidities
In line with the critically ill nature of the patient population,
a high level of comorbid disorders was recorded at study
entry. Comorbidities recorded in at least one quarter of the
study population included arterial hypertension (73%), hyper-
lipidemias (45%), renal failure and impairment (45%), dia-
betes mellitus (43%), and mitral valvular disorders (38%).
Surgical and medical procedures that had been performed in
at least one quarter of the study population before study entry
included cardiac device implants (42%) and coronary artery
bypass grafts or percutaneous coronary interventions (38%).
Recorded drug use (medications taken on admission to
hospital before the infusion and/or during or after the invasive
part of the study) included medications for diseases of the
cardiovascular system (100%) and anticoagulation or platelet
inhibition (93%). Specifically, for part B (n33), the number
of patients with recorded drug use, categorized by drug type,





























































































































































































































Figure 2. Effect of intravenous infusion of cinaciguat on (A) PCWP, (B) mean PAP, (C) mean RAP, (D) SVR, (E) PVR, and (F) cardiac out-
put (CO) in patients with ADHF (n30). *P0.0125, **P0.000125 vs baseline. Note that the distribution of patients to the doses in part
B is shown in Figure 1B.
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giotensin II receptor blockers, 31 (94%); -blockers, 28
(85%); spironolactone, 27 (82%); diuretics, 32 (97%); and
digitalis, 13 (39%). Corresponding values for all patients
(parts A and B; n60) were angiotensin-converting enzyme
inhibitors/angiotensin II receptor blockers, 56 (93%);
-blockers, 52 (87%); spironolactone, 50 (83%); diuretics, 58
(97%); and digitalis, 28 (47%).
Part A: Dose Finding
Overall, 27 patients participated in part A, the dose-finding
part of the study. Responses in PCWP and SBP were
analyzed to determine the optimal starting dose for part B of
the study.
Pulmonary Capillary Wedge Pressure
MeanSD PCWP of patients in cohort 1 of part A was
23.34.7 mm Hg at baseline, decreasing to 18.35.9 mm Hg
at the end of the 6-hour infusion period with cinaciguat and
increasing slightly again to 19.66.7 mm Hg at the end of the
2-hour postinfusion follow-up period. For patients in cohort 2
of part A, the meanSD PCWP at these 3 time points was
21.63.8, 13.44.5, and 15.75.4 mm Hg, respectively.
The proportion of patients responding to cinaciguat was 75%
(6 of 8 patients) in cohort 1 and 100% (7 of 7 patients) in
cohort 2. For the 100-g/h dose, the starting dose for part B,
the proportion of responders in both cohorts was 53.3% (8 of
15 patients), whereas for the 200-g/h dose, it was 80.0% (12
of 15 patients).
Systolic Blood Pressure
MeanSD SBP of patients in cohort 1 of part A was 126.8
23.2 mm Hg at baseline, decreasing to 116.820.2 mm Hg at the
end of the 6-hour infusion period with cinaciguat and increasing
again to 125.822.4 mm Hg at the end of the 2-hour postinfusion
follow-up period. For patients in cohort 2 of part A, the
meanSD SBP at these 3 time points was 121.611.2,
115.320.5, and 128.120.5 mm Hg, respectively. In the
100-g/h dose group, the starting dose for part B, 40.0% (6 of
15) of patients achieved a reduction of SBP to 110 mm Hg.
In the 200-g/h dose group, the proportion was 46.7% (7 of
15 patients).
Part B: Hemodynamic Responses
On the basis of the results from part A, an intravenous
infusion starting dose of 100 g/h cinaciguat was chosen for
patients in part B, the proof-of-concept part of the study.
Individual titration to target blood pressure was allowed after
each 2-hour period. The final doses of cinaciguat after 6 hours
of infusion were 50 g/h (n2), 200 g/h (n12), and 400
g/h (n16) (Table 2).
Hemodynamic Parameters
Six-hour infusions with cinaciguat in part B resulted in a
decrease in SBP, diastolic blood pressure, mean arterial
pressure, PCWP, PAP, RAP, SVR, and PVR and an increase
in cardiac output, without a marked increase in heart rate
(Table 3). Values for these hemodynamic parameters started
returning toward baseline levels once the cinaciguat infusion
was stopped (Table 3). Hemodynamic parameters worsened
again within 2 hours of the end of infusion, even though other
interventions such as treatment diuretics and oxygen were
still being provided. Figure 2 shows changes from baseline in
PCWP, mean PAP, RAP, SVR, mean PVR, and cardiac
output at 2, 4, and 6 hours of infusion with cinaciguat and at
2 hours after infusion. Changes from baseline were signifi-
cant at all time points during infusion with cinaciguat for
these parameters except for PVR, for which changes from
baseline did not reach significance at the 2- and 4-hour
infusion time points, and RAP during the 2-hour follow-up
period (Figure 2).
Responder Rate
Six-hour infusions with cinaciguat in part B significantly
decreased the meanSD PCWP from 24.15.4 mm Hg at
baseline to 17.25.2 mm Hg at the end of the infusion period
(P0.0001 versus baseline). The proportion of patients re-
sponding to cinaciguat was 53% after 2 hours, 83% after 4
hours, and 90% after 6 hours (Figure 3).
Dyspnea score
Of the 30 patients with valid dyspnea score data in part B, 26
reported an improvement in dyspnea score at the end of the
infusion period, and 28 reported an improvement at the end of
the 18-hour follow-up period.
Neurohormones
At baseline, plasma values of vasoconstrictors (represented
by plasma renin activity and noradrenaline) and vasodilators
(represented by atrial natriuretic peptide and NT-proBNP)
were pathologically elevated as a result of HF (Table 3).
Table 1. Demographics and Patient Characteristics at
Baseline







Male, n (%) 10 (83) 14 (93) 31 (94)
Mean age (range), y 69.2 (50–87) 65.5 (41–84) 64.7 (36–81)
Mean (SD) BMI, kg/m2 27.0 (5.9) 27.4 (5.9) 28.6 (4.6)
Mean (SD) NT-proBNP,
pg/mL*
19 059 (8119) 18 140 (7676) 21 199 (11 029)
HF origin, n (%)
Ischemic 6 (50) 9 (60) 21 (64)
Nonischemic 6 (50) 6 (40) 12 (36)
BMI indicates body mass index.
*The numbers of patients with values for mean NT-proBNP were as follows:
part A cohort 1, n8; part A cohort 2, n4; part B, n28.
Table 2. Cinaciguat Dosing Distribution in Part B
Study Time
0 h 2 h 4 h 6 h Patients, n
100 100/50 50/50 50 2
100 100/200 200 200 12
100 100/200 200/400 400 16
Doses were measured in g per hour.
2784 Circulation June 2, 2009
 by on January 6, 2010 circ.ahajournals.orgDownloaded from 
Although there was no significant change in atrial natriuretic
peptide and NT-proBNP levels 6 hours after cinaciguat
infusion, noradrenaline (217.3 ng/L) and plasma renin activ-
ity (4.53 ng · mL1 · h1) increased significantly compared
with baseline.
Safety
Of the 60 patients who were treated and were valid for the
safety evaluation, 36 did not report any adverse events.
Twenty-four patients reported a total of 42 treatment-
emergent adverse events (intensity: mild, n27; moderate,
n13; severe, n2). The most frequently reported treatment-
emergent adverse event was hypotension (6 patients, all with
symptomatic hypotension; Table 4). Three adverse events
were serious: cardiac failure after elective surgery for an
implantable cardioverter-defibrillator occurring 5 days after
the last dose of study drug and resulting in death, non–ST-
elevation myocardial infarction (without preceding hypoten-
sion) that resolved after remedial drug therapy, and intracar-
diac thrombus. None of the serious adverse events were
considered related to the study drug. Fourteen treatment-
emergent adverse events in 13 patients were considered to be
drug related (intensity: mild, n11; moderate, n3 [hypo-
tension, n2; dyspnea, n1]). Four patients discontinued
treatment with the study drug as a result of 5 adverse events.
Of these, hypotension (n2) and dyspnea (n1) were con-
sidered drug related; back pain (n1) and respiratory failure
(n1) were considered not drug related.
Laboratory values were typical for this study population
and did not show any specific abnormality related to ci-
naciguat treatment. In particular, there did not appear to be
increases in serum creatinine levels in response to cinaciguat
treatment. Mean creatinine levels in part B (n33) at baseline
(1.34 mg/dL) had changed little by 24 hours after the start of
the cinaciguat infusion (1.45 mg/dL) or 48 hours after the
start of the infusion (1.40 mg/dL).
Table 3. Effect of 6-Hour Intravenous Infusion of Cinaciguat on Hemodynamic Parameters and Biomarkers in Part B
Parameter Baseline End of 6-Hour infusion 2 h After Infusion 6-h Infusion Versus Baseline P
SBP, mm Hg 119.0 (18.7) 105.7 (16.6) 112.0 (16.9) 13.9 (13.9) 0.0001
DBP, mm Hg 72.6 (12.0) 57.9 (14.1) 62.6 (10.2) 14.5 (12.9) 0.0001
MAP, mm Hg 88.1 (12.6) 73.8 (12.8) 79.1 (10.7) 14.3 (12.4) 0.0001
PCWP, mm Hg 25.0 (4.5) 17.2 (5.2) 19.4 (5.6) 7.9 (3.0) 0.0001
Mean PAP, mm Hg 36.0 (6.0) 29.4 (6.2) 32.8 (6.3) 6.5 (5.2) 0.0001
RAP, mm Hg 13.0 (4.0) 10.1 (4.1) 11.5 (4.2) 2.9 (2.6) 0.0001
SVR, dynes  s  cm5 1581 (603) 971 (438) 1133 (462) 597 (424) 0.0001
PVR, dynes  s  cm5 223 (104) 180 (87) 215 (71) 43 (88) 0.0117
Cardiac output, L/min 4.24 (1.34) 5.92 (1.79) 5.24 (1.36) 1.68 (1.10) 0.0001
Heart rate, bpm 76.7 (17.0) 81.1 (16.7) 78.7 (15.8) 4.4 (1.2) 0.0246
ANP, nmol/L 11.86 (6.64) 11.14 (5.68) 11.10 (5.14) 0.73 (2.94) 0.2032
NT-proBNP, pg/mL 21 199 (11,029) 22 148 (11,915) 21 189 (10,953) 948 (3694) 0.1855
cGMP, nmol/L 15.28 (7.31) 18.22 (8.49) 17.17 (9.07) 2.94 (4.84) 0.0034
PRA, ng  mL1  h1 6.12 (6.48) 10.65 (9.52) 8.37 (8.72) 4.53 (6.73) 0.0014
Noradrenaline, ng/L 605.4 (315.3) 822.6 (350.8) 783.7 (363.5) 217.3 (294.9) 0.0006
DBP indicates diastolic blood pressure; MAP, mean arterial pressure; ANP, N-terminal atrial natriuretic peptide; and PRA, plasma-renin activity. Values are mean
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Figure 3. Proportion of patients with ADHF responding to intra-
venous cinaciguat according to the magnitude in reduction of
PCWP (n30). aDecrease in PCWP of at least 4 mm Hg.
Table 4. Patients With Treatment-Emergent, Drug-Related
Adverse Events









Total patients* 4 (33) 6 (40) 3 (9) 13 (22)
Nausea 1 (8) 1 (7) 2 (3)
Malaise … … 1 (3) 1 (2)
Headache … 1 (7) … 1 (2)
Somnolence 1 (8) … … 1 (2)
Dyspnea … 1 (7) … 1 (2)
Hot flush 2 (17) … … 2 (3)
Hypotension … 4 (27) 2 (6) 6 (10)
Patients valid for safety: n60.
*With any treatment-emergent, drug-related adverse event.
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Discussion
These first clinical results with cinaciguat in patients with
ADHF clearly demonstrate the clinical potential of ci-
naciguat. Results from a recently completed phase I clinical
trial showed that cinaciguat had a favorable safety profile and
was well tolerated in healthy male volunteers.16 In the present
proof-of-concept study, cinaciguat had a favorable hemody-
namic efficacy and was well tolerated in patients with ADHF.
Administration of cinaciguat resulted in potent unloading of
the heart with venous and arterial vasodilatation, which was
associated with a decrease in PCWP, RAP, SVR, and PVR
and an increase in cardiac output in patients with ADHF with
a modest increase in heart rate. The decrease of PCWP and
RAP is a consequence primarily of venous vasodilatation,
whereas the decrease in SVR is a result of arterial vasodila-
tation. Importantly, there did not appear to be increases in
serum creatinine levels in response to cinaciguat treatment,
indicating that renal function was preserved.
As a result of arterial vasodilatation, the observed increase
in noradrenaline and plasma renin activity levels during
cinaciguat infusion was probably a result of arterial vasodi-
latation. The small changes in heart rate, which are clinically
insignificant, also have to be regarded in this setting. Reduced
left ventricular filling pressure at 6 hours is not reflected in
decreased plasma NT-proBNP concentrations. Reductions in
right and left ventricular filling pressures may result in a
reduction of NT-proBNP with a time-lag phase18 shown in a
large number of patients in the Safety and Efficacy of an
Intravenous Placebo-Controlled Randomized Infusion of Ul-
aritide in a Prospective Double-blind (SIRIUS) II study.19
NT-proBNP secretion usually requires a long-term stimu-
lus.20 Therefore, abrupt reductions in right and left ventricular
filling pressures may not directly result in a reduction of
NT-proBNP. The half-life of NT-proBNP is 120 minutes,
suggesting that hemodynamic changes could be reflected by
this test every 12 hours.20
The large majority of patients (90%) responded to ci-
naciguat by the end of the 6-hour infusion period, as defined
a priori by a reduction in PCWP of at least 4 mm Hg
compared with baseline. Dyspnea scores also improved in the
majority of patients, but the effect of cinaciguat on dyspnea
remains speculative in the absence of a control group. The
dyspnea scoring assessment used here is not validated but has
been used previously.17,19 Patient self-assessment, however,
may be affected by confounding variables (eg, if the patient
has a right heart catheter in place or if hemodynamic
parameters are known). We reduced potential bias by per-
forming dyspnea self-assessment before hemodynamic mea-
surements and by prohibiting investigators from discussing
these measurements or assisting patients in completing their
symptom evaluation. However, knowledge of the degree of
PCWP reduction by the nursing and medical staff still may
have affected a patient’s self-assessment.
The observed clinical improvement is likely to be a result
of the study drug in addition to other interventions such as
diuretics and oxygen. Moreover, it is important to note that
the positive hemodynamic effects observed during the ci-
naciguat infusion worsened after the infusion stopped, despite
ongoing general treatment. This implies that the hemodynam-
ic benefits observed were largely related to cinaciguat rather
than the general treatment.
A potential criticism of the study is that its uncontrolled
design may have resulted in an overestimation of the benefi-
cial hemodynamic effects of cinaciguat, given that the pla-
cebo group in VMAC had a 2-mm Hg, albeit insignificant,
decrease in PCWP by 3 hours. Moreover, failure of the
hemodynamic parameters to return fully to baseline levels by
2 hours after the infusion ceased may suggest that factors
other than the cinaciguat infusion (eg, bedrest and general
treatment) account for a proportion of the hemodynamic
improvements. Although this is a possibility, the half-life of
cinaciguat (12 to 18 minutes) means that residual cinaciguat
activity also may partly explain this phenomenon.16
The hemodynamic goals of effective therapy for ADHF are
a decrease in end-diastolic pressure of the left ventricle
(preload) and a decrease in afterload, resulting in an increase
of cardiac output. Furthermore, to be effective in ADHF, it
may be desirable for such a therapy to act independently of
NO because of conditions of oxidative stress in diseased
tissues. In recent decades, there has been only limited
advancement in the treatment of ADHF.21,22 Existing treat-
ment options include positive inotropic agents, vasodilators,
and diuretic drugs, as well as ultrafiltration and mechanical
support of ventilation.23,24 Although the vasodilator nesiritide
improves hemodynamics and symptoms in patients with
ADHF,17 it also has been linked to worsening renal function
in this patient group.25 Nesiritide may even increase prema-
ture mortality rates, although this is a subject of some
controversy and ongoing studies.26,27 Organic nitrates such as
nitroglycerin are widely used in the treatment of ADHF even
though there are limited data from clinical trials. Cotter et al24
reported that a strategy of high-dose isosorbide dinitrate and
low-dose furosemide was associated with improved outcomes
in ADHF compared with low-dose isosorbide dinitrate and
high-dose furosemide. However, the well-recognized devel-
opment of tolerance,28 together with their lack of effect on
oxidized and heme-free sGC, may limit the therapeutic value
of organic nitrates.10 Many preclinical observations indicate
that cinaciguat represents a new class of therapeutics that may
be useful in overcoming the tolerance developed during
sustained nitroglycerin therapy.14,29
Results from the present study show that cinaciguat has
promising cardiovascular effects resulting in a potent unload-
ing of the heart. They are also consistent with preclinical data
that suggested that patients with enhanced vasodilator re-
sponses to cinaciguat, but probably blunted vasodilator re-
sponse to NO donors, appear to be ideally suited for therapies
directed at restoring redox homeostasis, sGC activity, and NO
sensitivity.11–14 Cinaciguat thus has the potential to provide
important therapeutic advantages in ADHF.11 It is important
to acknowledge, however, that further studies are required
because this proof-of-concept study lacks placebo control or
comparison groups.
With regard to the pharmacokinetics of cinaciguat, it
should be noted that the plasma concentration–time profiles
of cinaciguat suggest dose-proportional pharmacokinetic be-
havior, with low interindividual variability in healthy volun-
teers.16 The plasma concentrations reached near-maximum
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levels within 30 minutes of the beginning of an infusion,
declining rapidly after the end of the infusion (dominant
half-life, 0.2 to 0.3 hours), with the hepatic biliary pathway
accounting for 94% of total clearance.16 Cinaciguat does not
appear to interact with cytochrome P450.16 Furthermore, no
potential clinically significant off-target effects have been
detected for cinaciguat, as tested with radioligand binding
assays (data on file at Bayer HealthCare AG). Thus, the
interaction between cinaciguat and sGC is highly specific.
This contrasts with the lack of specificity observed with
nitrovasodilators.30
Conclusions
Results from this first clinical study with cinaciguat in
patients with ADHF clearly demonstrate its promise. Ci-
naciguat has potent preload- and afterload-reducing effects,
as well as other cardiovascular benefits, and further investi-
gation of this promising new therapeutic strategy for HF is
warranted. A phase II study with infusion periods of 24 to 48
hours is currently enrolling patients.
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CLINICAL PERSPECTIVE
Therapies for managing acute decompensated heart failure are far from ideal; hospitalization rates and disease morbidity
continue to increase, as does the need for more treatment resources, and current pharmacotherapy has its limitations. Thus,
there is still a need for better therapies. Cinaciguat (BAY 58–2667) is the first of a new class of soluble guanylate cyclase
activators in clinical development for acute decompensated heart failure. It has a promising and novel mode of action,
stimulating cGMP synthesis by targeting soluble guanylate cyclase in its nitric oxide–insensitive, oxidized-ferric (Fe3), or
heme-free state. Therefore, cinaciguat also may be effective under oxidative stress conditions refractory to traditional
organic nitrate therapies for acute decompensated heart failure. The nonrandomized, uncontrolled, proof-of-concept study
described here is the first to investigate cinaciguat in patients with acute decompensated heart failure, demonstrating potent
preload- and afterload-reducing effects and maintenance of renal function. A 6-hour infusion of cinaciguat 50 to 400 g/h
led to significant reductions compared with baseline in pulmonary capillary wedge pressure (7.9 mm Hg), mean right
atrial pressure (2.9 mm Hg), mean pulmonary artery pressure (6.5 mm Hg), pulmonary vascular resistance (43.4
dynes · s · cm5), and systemic vascular resistance (597 dynes · s · cm5), while increasing heart rate by 4.4 bpm and
cardiac output by 1.68 L/min. The responder rate (pulmonary capillary wedge pressure decrease of 4 mm Hg compared
with baseline) was 90% after 6 hours. Cinaciguat was well tolerated. Thus, further investigation of cinaciguat is warranted
in this patient group.
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